Paracrine action of vascular endothelial growth factor in the human endometrium: Production and target sites, and hormonal regulation

Angiogenesis

Volumn 2, Issue 2, 1998, Pages 167-182

  Bausero, Pedro ^a   Cavaillé, Françoise ^b   Méduri, Geri ^a   Freitas, Sayonara ^a   Perrot Applanat, Martine ^a  

^a BICHAT HOSPITAL   (France)

^b HÔPITAL SAINT ANTOINE   (France)

Author keywords

Angiogenesis; Endometrium; Estradiol; Estradiol receptor; Receptor; Vascular endothelial growth factor

Indexed keywords

EID: 0000021343     PISSN: 09696970     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1009292506879     Document Type: Article

References (47)

1. Giudice L. The endometrial cycle. In: Adashi EY, Rock JA, Rosenwaks (eds), Reproductive Endocrinology, Surgery and Technology. Philadelphia: Lippincott-Raven 1996: 272-300.
2. Charnock-Jones DS, Sharkey AM, Rajput-Williams J, et al. Identification and localization of alternately spliced mRNAs for vascular endothelial growth factor in human uterus and estrogen regulation in endometrial carcinoma cell lines. Biol Reprod 1993; 48, 1120-1128.
3. Cullinan-Bove K, Koos RD. Vascular endothelial growth factor/vascular permeability factor expression on the rat uterus: rapid stimulation by estrogen correlates with estrogen-induces increases in uterine capillary permeability and growth. Endocrinology 1993; 133, 829-837.
4. Zhang L, Rees MCP, Bicknell R. The isolation and long-term culture of normal human endometrial epithelium and stroma. Expression of mRNAs for angiogenic polypeptides basally and on oestrogen and progesterone challenges. J Cell Sci 1995; 108, 323-331.
5. Shifren JL, Tseng JF, Zaloudek CJ, et al. Ovarian steroid regulation of vascular endothelial growth factor in human endometrium: implications for angiogenesis during the menstrual cycle and in the pathogenesis of endometriosis. J Clin Endocrinol Metab 1996; 81, 3112-3118.
6. Senger DR, Galli SJ, Dvorak AM, et al. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983; 219, 983-985.
7. Dvorak HF, Brown LF, Detmar M, et al. Vascular permeability factor/vascular endothelial growth factor, microvascular hypermeability, and angiogenesis. Am J Pathol 1995; 146, 1029.
8. Ferrara N, Davis-Smith T. The biology of vascular endothelial growth factor. Endocr Rev 1997; 18, 4-25.
9. Millauer B, Wizigmann-Voos S, Schnürch H, et al. High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell 1993; 72, 835-846.
10. Shibuya M, Yamaguchi S, Yamane A, et al. Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fms family. Oncogene 1990; 5, 519-524.
11. De Vries C, Escobedo JA, Ueno H, et al. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 1992; 255, 989-991.
12. Terman BI, Dougler-Vermaraen M, Carrion ME, et al. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial growth factor. Biochem Biophys Res Commun 1992; 187, 1579-1586.
13. Tischer E, Mitchell R, Hartman T, et al. The human gene for vascular endothelial growth factor: multiple protein are encoded through alternative exon splicing. J Biol Chem 1991; 266, 11947-11954.
14. Houck K, Ferrara N, Winer J, et al. The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol Endocrinol 1991; 5, 1806-1814.
15. Plouet J, Moro F, Bertagnoli S, et al. Extracellular cleavage of the vascular endothelial growth factor family 189 as a form by urokinase is required for its mitogenic effect. J Biol Chem 1997; 272, 13390-13396.
16. Delage G, Moreau J, Taupin JL, et al. In vitro endometrial secretion of human interleukin for DA cells/leukaemia inhibitory factor by explant cultures from fertile and infertile women. Human Reprod 1995; 10, 2483-2488.
17. Noyes RW, Hertig DT, Rock J. Dating the endometrial biopsy. Fertil Steril 1950; 1: 1-9.
18. Perrot-Applanat M, Deng M, Fernandez H, et al. Immunohistochemical localization of estradiol and progesterone receptors in human uterus throughout pregnancy. Expression in endometrial blood vessels. J Clin Endocrinol Metab 1994; 78, 216-224.
19. Garcia E, Bouchard P, De Brux J, et al. Use of immunocytochemistry of progesterone and estrogen receptors for endometrial dating. J Clin Endocrinol Metab 1988; 67, 80-88.
20. Perrot-Applanat M, Groyer-Picard MT, Vu Hai MT, et al. Immunocytochemical staining of progesterone receptor in paraffin sections of human breast cancers. Am J Pathol 1989; 135, 457-468.
21. Perrot-Applanat M, Lescop P, Milgrom E. The cytoskeleton and the cellular traffic of the progesterone receptor. J Cell Biol 1992; 119, 337-348.
22. Plouet J, Moro F, Bertagnolli S, et al. 1997 Extracellular cleavage of the vascular endothelial growth factor 189-amino acid form by urokinase is required for its mitogenic effect. J Biol Chem 1997; 272, 13390-13396.
23. Gitay-Goren H, Soker S, Vlodavsky I, et al. The binding of vascular endothelial growth factor to its receptors is dependent on cell surface-associated heparin-like molecules. J Biol Chem 1992; 267, 6093-6098.
24. Kirk D, Irwin JC. Normal human endometrium in cell culture. Methods Cell Biol 1980; 21, 51-77.
25. Osteen KG, Hill GA, Hargrove JT, et al. Development of a method to isolate and culture highly purified populations of stromal cells and epithelial cells from human endometrial biopsy specimen. Fertil Steril 1989; 52, 965-972.
26. Perrot-Applanat M, Cohen-Solal K, Milgrom E, et al. Progesterone receptor expression in human saphenous veins. Circulation 1995; 92, 2975-2983.
27. Keck PJ, Hauser SD, Krivi G, et al. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science 1989; 246, 1309-1312.
28. Haendler, Hofer-Warbinek R, Hofer E. Complementary DNA for human T-cell cyclophilin. EMBO J 1987; 6, 947-950.
29. Guerrin M, Scotet E, Malecaze F, et al. Overexpression of vascular endothelial growth factor induces cell transformation in cooperation with fibroblast growth factor 2. Oncogene 1997; 14, 463-471.
30. Li XL, Gregory J, Ahmed A. Immunolocalisation of vascular endothelial growth factor in human endometrium. Growth Factors 1994; 11, 277-282.
31. Torry DS, Holt VJ, Keenan JA, et al. Vascular endothelial growth factor in cycling human endometrium. Fertil Steril 1996; 66, 72-80.
32. Mosselman S, Polman J, Dijkema R. ERβ: identification and characterization of a novel human estrogen receptor. FEBS Lett 1996; 392, 49-53.
33. Iafrati MD, Karas RH, Aronovitz M, et al. Estrogen inhibits the vascular injury response in estrogen receptor a-deficient mice. Nat Med 1997; 3, 545-548.
34. Morales DE, Mc Gowan KA, Grant DS, et al. Estrogen promotes angiogenic activity in human umbilical vein endothelial cells in vitro and a in a murine model. Circulation 1995; 91, 755-763.
35. Dvorak HF, Sioussat TM, Brown LF, et al. Distribution of Vascular Permeability Factor (vascular endothelial growth factor) in tumors: concentration in tumor blood vessels. J Exp Med 1991; 174, 1275-1278.
36. Qu-Hong, Nagy JA, Senger DR, et al. Ultrastructural localization of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) to the abluminal plasma membrane and vesiculovascular organelles of tumor microvascular endothelium. J Histochem Cytochem 1995; 43, 381-389.
37. Lutty GA, McLeod S, Merges C, et al. Localization of Vascular Endothelial Growth Factor in human retina and choroid. Arch Ophtalmol 1996; 114, 971-977.
38. Flamme I, Von Reutern M, Drexler HCA, et al. Overexpression of Vascular Endothelial Growth Factor in the avian embryo induces hypervascularization and increased vascular permeability without alterations of embryonic pattern formation. Dev Biol 1995; 171, 399-414.
39. Cohen T, Gitay-Goren H, Sharon R, et al. VEGF121, a vascular endothelial growth factor (VEGF) isoform lacking heparin binding ability, requires cell-surface heparan sulfates for efficient binding to the VEGF receptors of human melanoma cells. J Biol Chem 1995; 270, 11322-11326.
40. Perrot-Applanat M. Physiological angiogenesis and hormones. In: Bikfalvi A (ed.), Comprehensive Vascular Biology. Berlin: Springer Verlag 1998; in press.
41. Roberts WG, Palade GE. Increased microvascular permeability and endothelial fenestration induced by vascular endothelial growth factor. J Cell Sci 1995; 108, 2369-2379.
42. Hyder SM, Stancel GM, Chiappetta C, et al. Uterine expression of vascular endothelial growth factor is increased by estradiol and tamoxifen. Cancer Res 1996; 56, 3954-3960.
43. Evans RM. The steroid and thyroid hormone receptor superfamily. Science 1988; 240, 889-895.
44. Beato M, Truss M, Chavez S. Control of transcription by steroid hormones. Ann NY Acad Sci 1996; 784, 93-123.
45. Carter BZ, Malter JS. Regulation of mRNA stability and its relevance to desease. Lab Invest 1991; 65, 610-621.
46. Johns A, Freay AD, Fraser W, et al. Disruption of estrogen receptor prevents 17β estradiol-induced angiogenesis in transgenic mice. Endocrinology 1996; 137, 4511-4513.
47. Voigt LF, Weiss NS, Chu J, et al. Progestogen supplementation of exogenous oestrogens and risk of endometrial cancer. Lancet 1991; 338, 274-277.